ESMO 2022 | Potential advantages of neoadjuvant immunotherapy for melanoma

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the possible clinical benefits of neoadjuvant immunotherapy for patients with melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.